Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison T Stopeck

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 21, 2015
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison T Stopeck, Karim Fizazi, Jean-Jacques Body, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2015
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison T Stopeck, Karim Fizazi, Jean-Jacques Body, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
Cancer|April 4, 2003
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseasesFrancis J Giles, Maureen A Cooper, Lewis Silverman, et al.
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2025
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapyAlison T Stopeck, Maysa Abu-Khalaf, Virginia Borges, et al.
Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 21, 2015
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison T Stopeck, Karim Fizazi, Jean-Jacques Body, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2015
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerAlison T Stopeck, Karim Fizazi, Jean-Jacques Body, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trialsAllan Lipton, Karim Fizazi, Alison T Stopeck, et al.
Cancer|April 4, 2003
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseasesFrancis J Giles, Maureen A Cooper, Lewis Silverman, et al.
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2025
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapyAlison T Stopeck, Maysa Abu-Khalaf, Virginia Borges, et al.
Journal of the National Cancer Institute|November 7, 2019
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307Julie R Gralow, William E Barlow, Alexander H G Paterson, et al.
Pageof 5